1. Scrip
  2. >>Business

Can Vasopharm Be First To EU Market With Novel TBI Drug?

 
• By Lucie Ellis-Taitt

Small German firm, Vasopharm, wants to be the first company to bring a therapeutic treatment to the European market for use in patients with traumatic brain injuries – but getting the drug through Phase III studies alone will be its biggest test yet.

Profile of a human head with a colorful symbol of neurons in the brain
Vaspharm's hopes rest on Phase III trial of TBI treatment • Source: Shutterstock

vasopharm GMBH, a small German pharma company, has big decisions ahead about its possible transition from a clinical-stage to commercial company. However, everything rides on the Phase III performance of its only compound, which has the potential to be the first pharmaceutical approved in Europe for traumatic brain injury.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business